Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.04, versus $0.57 reported last year. Revenue for the quarter came in at $159.1 million, versus $143.6 million reported last year.

GUIDANCE:

Supernus Pharma sees FY2022 revenue of $640-680 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.